Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906158 | 0.92 | MAPK1 (0.42) | MAPK1TSHRTDP1CYP1A2CYP3A4 | |
| SCHEMBL11656996 | 0.85 | MAPK1 (0.37) | MAPK1TSHRTDP1CYP1A2CYP3A4 | |
| SCHEMBL30229 | 0.83 | TSHR (0.36) | MAPK1TSHRTDP1CYP1A2CYP3A4 | |
| SCHEMBL11651615 | 0.82 | TSHR (0.42) | MAPK1TSHRTDP1 | |
| SCHEMBL5354530 | 0.81 | MAPK1 (0.34) | MAPK1CYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL6348131 | 0.81 | MAPK1 (0.34) | MAPK1CYP1A2CYP3A4CYP2C9HIF1A | |
| Hexylene Glycol SCHEMBL11422336 | 0.80 | MAPK1 (0.42) | MAPK1TSHRTDP1CYP1A2CYP3A4 | |
| SCHEMBL6348129 | 0.79 | MAPK1 (0.33) | MAPK1TSHR | |
| SCHEMBL11659759 | 0.79 | MAPK1 (0.33) | MAPK1TSHR | |
| SCHEMBL7757431 | 0.79 | MAPK1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027750-A1 | Continuous Extruder Process for Manufacturing Rheology-Modified Polyolefin for Cable Insulation Layer, and Related Products | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250353938-A1 | DYNAMICALLY CROSSLINKED POLYOLEFIN PRODUCED THROUGH A POST-REACTOR PROCESS WITH A DYNAMIC DISULFIDE CROSSLINKER | BRASKEM AMERICA INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250346695-A1 | ETHYLENE BASED CO/TERPOLYMERS CONTAINING A HIGH PURITY -S-S- BASED DYNAMIC CROSSLINKER TO PRODUCE AN IN-REACTOR DYNAMIC MATERIAL | BRASKEM AMERICA INC (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025235568-A1 | ETHYLENE BASED CO/TERPOLYMERS CONTAINING A HIGH PURITY -S-S- BASED DYNAMIC CROSSLINKER TO PRODUCE AN IN-REACTOR DYNAMIC MATERIAL | BRASKEM AMERICA, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250243302-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-07-31 | — | — | US | claimed |
| WO-2025129179-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-06-19 | — | — | WO | claimed |
| EP-4486823-A1 | OPEN CELL POLYMER FOAM COMPOSITION WITH TUNABLE TORTUOSITY AND METHOD OF MAKING THE SAME | Braskem S.A. (BR) | 2025-01-08 | — | — | EP | claimed |
| CN-118974149-A | Open cell polymer foam composition with adjustable tortuosity and preparation method thereof | 布拉斯科有限公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2023161726-A1 | OPEN CELL POLYMER FOAM COMPOSITION WITH TUNABLE TORTUOSITY AND METHOD OF MAKING THE SAME | BRASKEM S.A. (BR) | 2023-08-31 | — | — | WO | claimed |
| US-11613045-B2 | Continuous extruder process for manufacturing rheology-modified polyolefin for cable insulation layer, and related products | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-03-28 | — | — | US | claimed |
| EP-3248224-B1 | ELECTRONIC DEVICE MODULE | YPAREX B V (NL) | 2020-12-23 | — | — | EP | claimed |
| US-6197213-B1 | SCORCH PROTECTION ACHIEVED FOR THERMOPLASTIC RESINS AND ELASTOMER DURING COMPOUNDING WHEN USING A PEROXIDE FREE RADICAL CATALYST BY ALSO USING IN ADDITION A COMBINATION OF A HYDROQUINONE AND A SULFUR ACCELERATOR; SYNERGISTIC | ATOFINA CHEMICALS, INC. | 2001-03-06 | — | — | US | claimed |
| US-6069208-A | SYNERGISTIC SCORCH RETARDING COMBINATIONS | ELF ATOCHEM N.A., INC. (US) | 2000-05-30 | — | — | US | claimed |
| US-5912304-A | MIXING WITH HYDROQUINONE AND DITHIOCARBAMATE, THIURAM, THIAZOLE, OR SULFENAMIDE ACCELERATOR | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1999-06-15 | — | — | US | claimed |
| US-5876624-A | Scorch retarding crosslinking compositions comprising a hydroquinone, a sulfur accelerator, a coagent and a free radical initiator | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1999-03-02 | — | — | US | claimed |
| US-5798435-A | INCLUDES EPOXIDIZED SOYBEAN OIL RESIDUES | CARGILL, INCORPORATED (US) | 1998-08-25 | — | — | US | claimed |
| EP-0504920-B1 | Scorch retarding curing/crosslinking compositions | ATOCHEM NORTH AMERICA ELF (US) | 1998-07-08 | — | — | EP | claimed |
| EP-0423639-B1 | Peroxide masterbatches using polycaprolactone as the carrier | ATOCHEM NORTH AMERICA (US) | 1995-09-20 | — | — | EP | claimed |
| US-5238978-A | Homogeneous dispersion; safe storage and handling | ELF ATOCHEM NORTH AMERICA INC. (US) | 1993-08-24 | — | — | US | claimed |
| EP-0504920-A2 | Scorch retarding curing/crosslinking compositions | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1992-09-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027750-A1 | Continuous Extruder Process for Manufacturing Rheology-Modified Polyolefin for Cable Insulation Layer, and Related Products | SEC16A, RBM17, IDE | MAPK1 593/4885TSHR 3764/4885TDP1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.